With regard to the PHQ and GAD questionnaire, during Phase 1, 31.6% were above the cut-off for depression and 28.0% were above the cut-off for anxiety, while during Phase 2, 21.1% were above the cut-off for depression and 20.6% were above the cut-off for anxiety. This evidence concerns the gene GAD1 and depressive symptom measurement.